Mirum Pharmaceuticals Inc

Compare

703 Followers

MIRM Stock Chart & Stats

$72.20

-$0.27(-0.64%)

At close: Jan 08 4:00 PM EST

$72.20

-$0.27(-0.64%)

Day’s Range― - ―

52-Week Range$36.88 - $78.54

Previous CloseN/A

Volume92.82K

Average Volume (3M)706.77K

Market Cap

$3.63B

Enterprise Value$2.54B

Total Cash (Recent Filing)$304.55M

Total Debt (Recent Filing)$318.90M

Price to Earnings (P/E)―

Beta0.74

Next Earnings

Nov 04, 2025

EPS Estimate

-0.14

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.12

Shares Outstanding50,237,648

10 Day Avg. Volume422,425

30 Day Avg. Volume706,773

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.70

Enterprise Value/Revenue5.93

Enterprise Value/Gross Profit7.50

Enterprise Value/Ebitda-135.43

Forecast

1Y Price Target

$84.00

Price Target Upside16.34% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering12

Bulls Say, Bears Say

Bulls Say

EarningsMIRM reported another strong Livmarli quarter with $88mm in sales, beating analyst and consensus estimates by over 20%.

Growth ProspectsManagement believes a potential label expansion for Livmarli to patients with other ultra-rare cholestatic diseases could propel the drug to blockbuster status.

Product ApprovalLivmarli was approved in Japan for Alagille syndrome and progressive familial intrahepatic cholestasis, leading to a favorable pricing adjustment.

Bears Say

Mirum Pharmaceuticals News

Mirum Pharmaceuticals price target raised to $81 from $75 at Morgan Stanley

Morgan Stanley raised the firm’s price target on Mirum Pharmaceuticals (MIRM) to $81 from $75 and keeps an...

16d ago

MIRM

Mirum Pharmaceuticals Advances in Fragile X Syndrome Treatment Study

Mirum Pharmaceuticals (($MIRM)) announced an update on their ongoing clinical study. Study Overview: Mirum Pharmaceuticals is conducting a...

4d ago

MIRM

Mirum Pharmaceuticals’ Volixibat Study: A Potential Breakthrough for PBC Itching

Mirum Pharmaceuticals (($MIRM)) announced an update on their ongoing clinical study. Study Overview: Mirum Pharmaceuticals is conducting a...

4d ago

MIRM

Mirum Pharmaceuticals Advances Phase 3 Study on Maralixibat for Cholestatic Pruritus

Mirum Pharmaceuticals (($MIRM)) announced an update on their ongoing clinical study. Mirum Pharmaceuticals is conducting a Phase 3...

5d ago

MIRM

Mirum Pharmaceuticals’ LEAP-US Study: A Long-Term Look at Livmarli’s Impact

Mirum Pharmaceuticals (($MIRM)) announced an update on their ongoing clinical study. Study Overview: The LEAP-US study, officially titled...

5d ago

MIRM

Mirum Pharmaceuticals initiated with a Buy at TD Cowen

TD Cowen initiated coverage of Mirum Pharmaceuticals (MIRM) with a Buy rating and $95 price target The company...

1M ago

MIRM

Mirum Pharmaceuticals: Strong Buy Rating Backed by Robust Rare Disease Portfolio and Promising Growth Prospects

Joseph Thome, an analyst from TD Cowen, has initiated a new Buy rating on Mirum Pharmaceuticals (MIRM). Joseph...

1M ago

MIRM

Mirum Pharmaceuticals price target raised to $77 from $53 at JPMorgan

JPMorgan raised the firm’s price target on Mirum Pharmaceuticals (MIRM) to $77 from $53 and keeps an Overweight...

2M ago

MIRM

Mirum Pharmaceuticals completes enrollment in VISTAS study of volixibat

Mirum Pharmaceuticals (MIRM) announced the completion of enrollment in the Phase 2b VISTAS study of volixibat, an investigational...

2M ago

MIRM

Mirum Pharmaceuticals’ Volixibat Study: A Potential Game-Changer for PBC Treatment

Mirum Pharmaceuticals (($MIRM)) announced an update on their ongoing clinical study. Mirum Pharmaceuticals is conducting a study titled...

2M ago

MIRM

Mirum Pharmaceuticals’ Volixibat Study: A Potential Game-Changer for PSC Treatment

Mirum Pharmaceuticals (($MIRM)) announced an update on their ongoing clinical study. Mirum Pharmaceuticals is conducting a clinical study...

2M ago

MIRM

Mirum Pharmaceuticals files automatic mixed securities shelf

16:08 EDT Mirum Pharmaceuticals (MIRM) files automatic mixed securities shelf Published first on TheFly – the ultimate source...

3M ago

MIRM

Arm initiated, Adobe downgraded: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here...

3M ago

ARM

Mirum Pharmaceuticals resumed with a Buy at Stifel

Stifel analyst James Condulis resumed coverage of Mirum Pharmaceuticals (MIRM) with a Buy rating and $89 price target...

3M ago

MIRM

MIRM FAQ

What was Mirum Pharmaceuticals Inc’s price range in the past 12 months?

Mirum Pharmaceuticals Inc lowest stock price was $36.88 and its highest was $78.54 in the past 12 months.

What is Mirum Pharmaceuticals Inc’s market cap?

Mirum Pharmaceuticals Inc’s market cap is $3.63B.

When is Mirum Pharmaceuticals Inc’s upcoming earnings report date?

Mirum Pharmaceuticals Inc’s upcoming earnings report date is Nov 04, 2025 which is in 3 days.

How were Mirum Pharmaceuticals Inc’s earnings last quarter?

Mirum Pharmaceuticals Inc released its earnings results on Aug 06, 2025. The company reported -$0.12 earnings per share for the quarter, beating the consensus estimate of -$0.326 by $0.206.

Is Mirum Pharmaceuticals Inc overvalued?

According to Wall Street analysts Mirum Pharmaceuticals Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Mirum Pharmaceuticals Inc pay dividends?

Mirum Pharmaceuticals Inc does not currently pay dividends.

What is Mirum Pharmaceuticals Inc’s EPS estimate?

Mirum Pharmaceuticals Inc’s EPS estimate is -0.14.

How many shares outstanding does Mirum Pharmaceuticals Inc have?

Mirum Pharmaceuticals Inc has 50,237,648 shares outstanding.

What happened to Mirum Pharmaceuticals Inc’s price movement after its last earnings report?

Mirum Pharmaceuticals Inc reported an EPS of -$0.12 in its last earnings report, beating expectations of -$0.326. Following the earnings report the stock price went up 12.043%.

Which hedge fund is a major shareholder of Mirum Pharmaceuticals Inc?

Currently, no hedge funds are holding shares in MIRM

Mirum Pharmaceuticals Stock Smart Score

Neutral

Fundamentals

Return on Equity

-24.19%

Trailing 12-Months

Asset Growth

9.85%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Mirum Pharmaceuticals Inc

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for patients with rare liver diseases. The company is primarily engaged in the development of treatments that address unmet medical needs in the field of hepatology. Its core products include Maralixibat, a drug designed for the treatment of cholestatic liver diseases, and other candidates targeting various liver conditions.

Mirum Pharmaceuticals (MIRM) Earnings & Revenues

Historic Earnings Reports

MIRM Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call reflects a strong performance by Mirum Pharmaceuticals, highlighted by significant revenue growth and positive pipeline developments. While there are challenges such as high operating expenses and variability in international sales, the positive aspects significantly outweigh the negatives.View all MIRM earnings summaries

MIRM Stock 12 Month Forecast

Average Price Target

$84.00

▲(16.34% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"39":"$39","96":"$96","53.25":"$53.3","67.5":"$67.5","81.75":"$81.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":95,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$95.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":84,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$84.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":72,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$72.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[39,53.25,67.5,81.75,96],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,73,74.6923076923077,76.38461538461539,78.07692307692308,79.76923076923077,81.46153846153847,83.15384615384616,84.84615384615384,86.53846153846153,88.23076923076923,89.92307692307692,91.61538461538461,93.3076923076923,{"y":95,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,73,73.84615384615384,74.6923076923077,75.53846153846153,76.38461538461539,77.23076923076923,78.07692307692308,78.92307692307692,79.76923076923077,80.61538461538461,81.46153846153847,82.3076923076923,83.15384615384616,{"y":84,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,73,72.92307692307692,72.84615384615384,72.76923076923077,72.6923076923077,72.61538461538461,72.53846153846153,72.46153846153847,72.38461538461539,72.3076923076923,72.23076923076923,72.15384615384616,72.07692307692308,{"y":72,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":40.12,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.4,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.21,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":41.35,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":48.88,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.57,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":44.04,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.42,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.97,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":48.39,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":52.02,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":74.34,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":73,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >